Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric J Devor

Showing results (41-50 of 70) with videos related to

Pageof 7
Sort By:
International Journal of Oncology|March 25, 2017
p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancersEric J Devor, Jesus Gonzalez-Bosquet, Akshaya Warrier, et al.
Molecular Endocrinology (Baltimore, Md.)|May 29, 2004
Modulation of ligand selectivity associated with activation of the transmembrane region of the human follitropin receptorLucia Montanelli, Joost J J Van Durme, Guillaume Smits, et al.
Clinical Obstetrics and Gynecology|December 27, 2019
Characterization of a TP53 Somatic Variant of Unknown Function From an Ovarian Cancer Patient Using Organoid Culture and Computational ModelingJianling Bi, Kristina W Thiel, Jacob M Litman, et al.
Current Pharmaceutical Design|July 30, 2013
Epigenetic modification restores functional PR expression in endometrial cancer cellsShujie Yang, Xue Xiao, Yichen Jia, et al.
BMC Plant Biology|September 17, 2008
Small RNA regulation of ovule development in the cotton plant, G. hirsutum LIbrokhim Y Abdurakhmonov, Eric J Devor, Zabardast T Buriev, et al.
Cancers|February 26, 2025
Enhancing Progestin Therapy with a Glucagon-Like Peptide 1 Agonist for the Conservative Management of Endometrial CancerAndrea R Hagemann, Ian S Hagemann, David G Mutch, et al.
American Journal of Cancer Research|July 10, 2020
Loss of progesterone receptor through epigenetic regulation is associated with poor prognosis in solid tumorsYiyang Li, Cheng Huang, Tamar Kavlashvili, et al.
International Journal of Oncology|November 12, 2014
TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinomaPavla Brachova, Samuel R Mueting, Matthew J Carlson, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|March 27, 2015
Vasopressin: the missing link for preeclampsia?Jeremy A Sandgren, Sabrina M Scroggins, Donna A Santillan, et al.
Disease Markers|January 17, 2019
Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 MutationsXiangbing Meng, Shujie Yang, Yujun Li, et al.
Pageof 7

Showing results (41-50 of 70) with videos related to

Sort By:
Pageof 7
International Journal of Oncology|March 25, 2017
p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancersEric J Devor, Jesus Gonzalez-Bosquet, Akshaya Warrier, et al.
Molecular Endocrinology (Baltimore, Md.)|May 29, 2004
Modulation of ligand selectivity associated with activation of the transmembrane region of the human follitropin receptorLucia Montanelli, Joost J J Van Durme, Guillaume Smits, et al.
Clinical Obstetrics and Gynecology|December 27, 2019
Characterization of a TP53 Somatic Variant of Unknown Function From an Ovarian Cancer Patient Using Organoid Culture and Computational ModelingJianling Bi, Kristina W Thiel, Jacob M Litman, et al.
Current Pharmaceutical Design|July 30, 2013
Epigenetic modification restores functional PR expression in endometrial cancer cellsShujie Yang, Xue Xiao, Yichen Jia, et al.
BMC Plant Biology|September 17, 2008
Small RNA regulation of ovule development in the cotton plant, G. hirsutum LIbrokhim Y Abdurakhmonov, Eric J Devor, Zabardast T Buriev, et al.
Cancers|February 26, 2025
Enhancing Progestin Therapy with a Glucagon-Like Peptide 1 Agonist for the Conservative Management of Endometrial CancerAndrea R Hagemann, Ian S Hagemann, David G Mutch, et al.
American Journal of Cancer Research|July 10, 2020
Loss of progesterone receptor through epigenetic regulation is associated with poor prognosis in solid tumorsYiyang Li, Cheng Huang, Tamar Kavlashvili, et al.
International Journal of Oncology|November 12, 2014
TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinomaPavla Brachova, Samuel R Mueting, Matthew J Carlson, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|March 27, 2015
Vasopressin: the missing link for preeclampsia?Jeremy A Sandgren, Sabrina M Scroggins, Donna A Santillan, et al.
Disease Markers|January 17, 2019
Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 MutationsXiangbing Meng, Shujie Yang, Yujun Li, et al.
Pageof 7